Steven Cohen's LGND Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 16,700 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $2.96 M, representing 0.00% of the portfolio. First purchased in 2020-Q3, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in LGND, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 51,831 shares. Largest reduction occurred in Q2 2022, reducing 82,600 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2020 | +2,269 | New Buy | 2,269 | $95.20 |
| Q4 2020 | -2,269 | Sold Out | 2,269 | $0.00 |
| Q4 2021 | +54,100 | New Buy | 54,100 | $154.45 |
| Q1 2022 | +31,400 | Add 58.04% | 85,500 | $112.49 |
| Q2 2022 | -82,600 | Reduce 96.61% | 2,900 | $89.31 |
| Q3 2022 | -2,900 | Sold Out | 2,900 | $0.00 |
| Q1 2023 | +81 | New Buy | 81 | $73.86 |
| Q2 2023 | -81 | Sold Out | 81 | $0.00 |
| Q3 2025 | +16,700 | New Buy | 16,700 | $177.14 |
Steven Cohen's Ligand Pharmaceuticals Incorporated Investment FAQs
Steven Cohen first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q3 2020, acquiring 2,269 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Ligand Pharmaceuticals Incorporated (LGND) for 21 quarters since Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q4 2021, adding 54,100 shares worth $8.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 16,700 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $2.96 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 85,500 shares, as reported at the end of Q1 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.